Overview of Metrocor

Property	Description
Active Ingredient	Metronidazole
Forms	Tablet, IV Solution, Gel, Cream
Pharmacological Class	Nitroimidazole Antimicrobial Agent
General Purpose	Targeting anaerobic bacteria and protozoa
Origin	Synthetic Compound

Defining Metrocor: Type, Composition, and Origin

Metrocor is a trade designation for a pharmaceutical preparation containing the single active ingredient metronidazole, a synthetic compound classified as a Nitroimidazole Antimicrobial Agent. This medication is fundamentally an antibiotic and antiprotozoal agent, defined by its chemical structure, 2-methyl-5-nitroimidazole-1-ethanol (C6H9N3O3). The drug is entirely manufactured through synthetic processes, establishing its origin as a chemically derived substance rather than one extracted from natural sources. Metronidazole is commonly used because it is clinically recognized for effectively killing certain types of susceptible germs that are responsible for infections.

What Physical Forms of Metronidazole Are Available?

The active ingredient metronidazole is widely available in several dosage form(s) to ensure effective delivery to the infection site. The available preparations include forms for systemic and localized use, such as the common oral tablet and the sterile solution for intravenous infusion (parenteral preparation). For treatments targeting mucosal or skin surfaces, the medication is prepared in topical/local preparations, including various creams and gels, each utilizing an appropriate base or vehicle, such as an aqueous solution or a polymer gel base. The unique nitroimidazole structure of metronidazole provides activity against a crucial range of infectious organisms, establishing its importance in this therapeutic class.

General Purpose: What Metrocor Targets in the Body

The general purpose of Metrocor is to eliminate infections by specifically targeting two distinct classes of harmful microorganisms: obligate anaerobic bacteria and certain protozoa. This medication achieves its effect through selective toxicity, activating only inside these susceptible pathogens that thrive in conditions of low oxygen concentration. By concentrating its destructive potential on these organisms, the medication serves the primary function of clearing infections sustained by these specific microbial threats. Its utility in targeting infections that are resistant to typical oxygen-dependent antibiotics is a key differentiating factor.

What side effects are possible with Metrocor?

Possible Side Effects and Safety Information

The official safety profile for Metrocor (metronidazole) details adverse reactions across several physiological systems, with classifications based strictly on clinical data reviewed by regulatory authorities.

Adverse Reaction Categories

Adverse events are generally grouped by the affected organ system and documented frequency. Common adverse reactions frequently cited in regulatory documents involve the Gastrointestinal System, including nausea, vomiting, diarrhea, and abdominal cramps. A metallic taste and headache are also commonly reported effects.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights specific, clinically serious, and rare adverse reactions primarily associated with the Nervous System (Neurological Disorders). These include reports of convulsive seizures, encephalopathy, aseptic meningitis, and peripheral neuropathy (numbness or tingling). Official prescribing information notes that nervous system effects have been associated with long-term exposure to the medication.

Safety restrictions include a contraindication for individuals with a prior history of hypersensitivity to metronidazole or related compounds. The medication is also contraindicated in patients with Cockayne syndrome due to the risk of severe acute liver failure. The official labeling specifies that consuming alcohol concurrently with Metrocor may result in a recognized disulfiram-like reaction.

Overdose and Emergency Response

Overdose and When to Seek Urgent Help

Overdose with Metrocor (metronidazole) can lead to serious adverse effects, predominantly involving the nervous system. The most significant documented overdose presentations include convulsive seizures and a condition known as peripheral neuropathy, which is often characterized by numbness, tingling, or pain, particularly in the extremities.

Key Overdose Manifestations

System Affected	Documented Overdose Signs
Neurologic	Convulsive seizures, peripheral neuropathy (e.g., numbness, paresthesia, ataxia)
Gastrointestinal	Nausea, vomiting, loss of muscle coordination, ataxia (often reported with high single oral doses)

Risk Factors and Required Actions

High single oral doses (e.g., up to 15 grams) have been reported in accidental and attempted overdoses, leading to symptoms like nausea, vomiting, and loss of muscle coordination (ataxia). In some patients, especially those with severe hepatic disease, the drug may be metabolized more slowly, resulting in accumulation and an increased risk of toxicity. Elderly patients may also require closer monitoring due to altered pharmacokinetics.

Immediate medical help is required if any abnormal neurologic signs appear, as this demands a prompt re-evaluation of the treatment. There is no specific antidote for metronidazole overdose; therefore, management involves symptomatic and supportive care. In cases of overdose, emergency services or a poison control center should be contacted immediately.

Therapeutic Uses of Metrocor

What Metrocor Treats: Main Uses and Benefits

Metrocor is generally used across clinical settings and is relevant for easing the symptoms associated with conditions involving severe infections caused by susceptible anaerobic bacteria, which are pathogens associated with low-oxygen environments. This medicine is relevant within therapeutic areas involving symptoms linked to organ-specific functional stress, such as in the GI tract, skin, heart, bone, lung, and nervous system. It helps address symptom clusters related to systemic imbalance and acute, localized inflammation, such as high fever and symptoms related to physical discomfort, providing support that helps ease the overall symptom burden.

The medicine is also commonly used across conditions involving episodic or fluctuating manifestations that present with significant symptomatic burden. It is applied in addressing symptoms that interfere with daily functioning, including pronounced diarrhea, physical discomfort, and symptoms that create noticeable physiological strain, such as abnormal vaginal discharge or odor. This approach may assist with maintaining functional stability during these symptomatic periods.

Quick Fact: Support for Inflammation and Discomfort The medication is considered relevant for easing symptoms that interfere with daily comfort and is commonly used when short-term symptomatic assistance is needed across acute or localized infectious and inflammatory states.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Metrocor (Metronidazole)

Official regulatory documents define specific populations who are permitted to use the medicine, as well as those who are contraindicated or require restricted use based on pre-existing conditions.

Absolute Prohibitions (Contraindications)

Category	Contraindicated Populations
Allergy / Co-use	Patients with known hypersensitivity to Metronidazole or other nitroimidazole drugs, or those who have taken Disulfiram within the past 14 days.
Toxicity Risk	Patients with Cockayne Syndrome (due to risk of severe hepatotoxicity).
Substance Interaction	Consumption of alcohol or use of propylene glycol-containing products during therapy and for at least three days after stopping the medicine.

Conditional Use and Restrictions

Population Group	Restriction Summary
Organ Function	Caution is mandatory in severe hepatic impairment (Child-Pugh C) and in End-Stage Renal Disease (ESRD) due to metabolite accumulation, necessitating monitoring.
CNS/Blood	Use is with caution in patients with a history of Central Nervous System (CNS) diseases or pre-existing blood dyscrasias.
Pregnancy	Contraindicated for Trichomoniasis treatment during the first trimester of pregnancy.
Age	Use in the pediatric population is not established for all indications; monitoring is suggested for older adults due to increased likelihood of co-existing conditions.

What should I know about interactions with other medicines?

The interaction profile for Metrocor (metronidazole) is strictly defined by mandatory restrictions and specific pharmacokinetic and pharmacodynamic interactions documented in regulatory labeling.

Formal Restrictions and Timing Rules

Co-administration with Disulfiram is formally contraindicated and requires a mandatory two-week separation period to avoid the risk of psychotic reactions. The consumption of Alcohol/Ethanol or products containing Propylene Glycol is also contraindicated during therapy and for a minimum of three days following the last dose due to the risk of a disulfiram-like reaction.

Exposure-Modifying Medicinal Products

Metronidazole alters the systemic exposure of several co-administered medicines through pharmacokinetic interference, which may be classified as either increased or reduced exposure. The clearance of agents such as Busulfan, 5-Fluorouracil, Lithium, and Ciclosporin is reduced, leading to increased plasma concentrations and potential toxicity of those drugs. Conversely, co-administration with enzyme-inducing antiepileptics, specifically Phenytoin and Phenobarbital, reduces the half-life of metronidazole by accelerating its metabolism.

Pharmacodynamic Effects and Population Notes

Metronidazole exhibits a pharmacodynamic potentiation effect with oral Coumarin Anticoagulants (e.g., Warfarin), which is described as increasing the anticoagulant effect and the risk of bleeding. Furthermore, the official labeling notes that in patients with Severe Hepatic Impairment, the drug's metabolism is reduced, resulting in higher exposure to metronidazole and potentially intensifying the effects of these documented interactions.

Mechanism of Action

The mechanism of Metronidazole is dependent on the unique biological processes of susceptible pathogens, such as obligate anaerobic bacteria and certain protozoa. The drug acts as an inactive prodrug until it enters these organisms, where low-oxygen conditions and specific electron transport proteins (like ferredoxin) chemically reduce its nitro group. This reduction creates highly reactive nitroso free radicals. These short-lived, cytotoxic radicals then damage and fragment the pathogen's DNA, irreversibly blocking its ability to reproduce and synthesize essential proteins. The resulting physiological effect is the concentration-dependent destruction of susceptible microbial cells. In addition, the drug influences local host responses by modulating the function of immune cells such as neutrophils. This action results in the functional reduction of local host inflammatory cell activity and associated oxidative tissue damage.

Dosage and Administration Information

Instruction Map: How to use Metrocor — Official Administration Guidelines

This map details the instructions for administering Metrocor (Metronidazole).

Administration Scope

Category	Official Instruction
Route of Administration	Systemic use is approved via Oral (tablet, capsule, suspension) and Intravenous (IV) routes. Topical/Vaginal administration is also a labeled route of use.
Dosing Schedule	For systemic anaerobic infections, a common regimen involves a loading dose (15 mg/kg IV) followed by a maintenance dose (7.5 mg/kg IV or oral) every 6 hours. The maximum daily dose should not exceed 4 g.
Timing in relation to meals (if applicable)	Immediate-release oral forms may be taken with food. Extended-release tablets must be administered on an empty stomach (1 hour before or 2 hours after a meal).
Preparation requirements (if applicable)	IV infusion must be administered slowly over a period of 30 to 60 minutes. IV preparation may require neutralization with sodium bicarbonate prior to administration.
Age-group administration rules	A 50% dose reduction is recommended in patients with severe (Child-Pugh C) hepatic impairment. Pediatric dosing for certain uses is calculated based on body weight (mg/kg/day).
Missed-dose rules	If a dose is missed, instructions generally advise taking the missed dose as soon as remembered and returning to the normal schedule, unless it is almost time for the next dose.
Special procedural conditions	Extended-release tablets must be swallowed whole and must not be crushed or chewed. Prophylactic use must be discontinued within 12 hours after surgery.

Instruction Classifications (High-Level)

Administration method type: Oral, Intravenous (IV), and Topical/Vaginal.
Frequency pattern: Typically multiple times daily (every 6 or 8 hours) or as a single-dose regimen, for a defined course duration.
Use-context constraints: Use is constrained by the formulation (must take extended-release on an empty stomach) and the patient’s clinical status (hepatic function).

Resulting Procedural Structure

Official step sequence:

Select the required dosage form (Oral or IV) and confirm the mg/kg or fixed dose for the maintenance regimen.
Administer the IV solution over 30 to 60 minutes following the necessary preparation steps.
For oral administration, ensure that extended-release forms are taken whole and on an empty stomach.
Continue administration at the specified frequency (e.g., every 8 hours) for the prescribed duration (e.g., 5 to 10 days).

Connection to the overall use protocol: The instructions establish a precise, time-limited regimen that defines the route, calculated amount, and frequency for the drug’s delivery. This protocol governs the standardized use of the medicine, including specific requirements for administration timing (with/without food) and mandatory dose adjustment in the presence of severe hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Metrocor

Evidence for Use in Serious Anaerobic Infections

The clinical evaluation of Metrocor for serious systemic infections is supported by Randomized Controlled Trials (RCTs) and Systematic Reviews. Research was studied for use within multi-drug treatment plans, particularly for hospitalized patients dealing with severe infections. Researchers examined specific endpoints such as clinical status indicators and the measurement of microorganism presence following the defined course of treatment. The populations were evaluated in trials included typical adults as well as subgroups with conditions like hepatic or renal impairment. The findings describe patterns observed during the immediate and short-term follow-up periods, such as the Test of Cure (TOC) assessment. However, the existing evidence for serious anaerobic infections is limited regarding the use of Metrocor as a single-drug therapy, as the research primarily focuses on combination regimens.

Research Supporting Use in Bacterial Vaginosis and Protozoal Infections

Evidence for use in infections caused by specific protozoa or anaerobic bacteria like Bacterial Vaginosis was evaluated in multiple Randomized Controlled Trials (RCTs) and comparative studies. The primary populations were evaluated in research consisting of non-pregnant adult women. In these trials, researchers examined a composite endpoint of Therapeutic Cure, which means they looked for the simultaneous measurement of clinical status indicators and the measurement of microorganism presence. The studies monitored the evolution of symptoms over these defined time intervals, and the evidence contributes to understanding symptom patterns following treatment. A key limitation is that follow-up durations were limited to the immediate post-treatment period (typically 28 days).

What Research Gaps and Uncertainty Remain

The evidence base has several known limitations. In the treatment of serious infections, the available data is heavily skewed toward combination therapy, meaning that evidence on using Metrocor alone is limited. Furthermore, research on obstetrical outcomes studied in pregnant women, a critical risk of bias and significant heterogeneity (variability) was observed in some studies. The evidence highlights what is known — and what is still uncertain — about the medication’s use; Metrocor’s use in these high-risk areas is still being assessed by research to address a known evidence gap.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Metrocor (FAQ)

Q: Does Metrocor cause you to feel more tired during the day?

Official safety information reports that both 'unusual weakness or fatigue' and 'drowsiness' are among the possible adverse events associated with this medication. If such effects are experienced, official guidance recommends consulting with a healthcare professional.

Q: Do many people experience dizziness when they first start taking Metrocor?

Dizziness or lightheadedness is listed in official regulatory labeling as a reported adverse reaction. Some regulatory documents note that this is among the more common side effects that people experience.

Q: Is it necessary to take Metrocor at the exact same time every day?

Regulatory guidance emphasizes that the medicine should be taken 'exactly as directed' by your prescriber, following the frequency (e.g., every 8 hours) outlined in the instructions. Adherence to the prescribed regimen is generally important.

Q: How does Metrocor affect the heart rate?

Heart rhythm changes, such as a fast or irregular heartbeat, have been reported as serious adverse effects in the official safety profile. These effects have also been specifically noted in association with the concurrent consumption of alcohol while taking the medication.

Q: Do the side effects of Metrocor get better or worse over time?

Official warnings note that certain serious nervous system effects, such as peripheral neuropathy (tingling or numbness), have been associated with 'long-term exposure' to the medication. The association of these serious effects with 'long-term exposure' is a pattern noted in the official safety profile.

Q: Why would a doctor switch a patient from one medicine to Metrocor?

Metrocor (Metronidazole) is officially classified as a Nitroimidazole Antimicrobial Agent. Its therapeutic role is defined by its ability to target specific groups of harmful microorganisms, namely obligate anaerobic bacteria and certain protozoa, making it suitable for infections caused by these particular threats.

Q: How quickly does Metrocor start working after the first time you take it?

Pharmacokinetic studies indicate that the drug generally reaches its peak concentration in the bloodstream in approximately 1 to 4 hours, though this can vary depending on the specific dosage form and whether it is taken with food.

Q: Can taking Metrocor affect the results of a blood test?

The official labeling states that this drug may affect certain laboratory test results. For this reason, regulatory documents recommend specific monitoring of total and differential leukocyte (white blood cell) counts before and after therapy.

Q: What kind of foods or drinks should people pay attention to when taking Metrocor?

The most significant restriction is that official regulatory documents formally contraindicate the consumption of alcohol/ethanol or products containing propylene glycol. This restriction applies during therapy and for a minimum of three days following the last dose.

Q: Is Metrocor considered safe for older adults over 65?

Official labeling for older patients notes that the drug’s processing by the body may be altered in this population. Monitoring for adverse events is generally recommended when used in this population.

Q: Is there a generic version of Metrocor available?

Yes, Metronidazole is the generic name for the active ingredient in Metrocor. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have approved generic versions of the drug.

Q: Can Metrocor cause changes in weight or appetite?

Changes in appetite, including loss of appetite, and weight loss are listed in the official safety profile as possible adverse events. This information comes from regulatory-reviewed clinical data.

Q: Is Metrocor the same as metoprolol, or are they different?

They are different medicines. Official classification documents define Metrocor as a Nitroimidazole Antimicrobial Agent, which is an antibiotic used to treat infections. Metoprolol is classified in a different therapeutic class known as a beta-blocker.

Q: Are there known effects of Metrocor on sleep quality?

Official safety information lists 'trouble sleeping' and 'insomnia' among the possible nervous system adverse reactions that have been reported with the use of this medication.

Q: Does Metrocor interact with birth control pills?

Official labeling notes that the effectiveness of estrogen-containing birth control pills may be impaired by co-administration with this drug. It is recommended to discuss this potential interaction with a healthcare professional.

Q: Can Metrocor affect mood or cause feelings of depression?

Official safety information includes 'depression,' 'irritability,' and 'mood changes' in the list of possible nervous system adverse reactions that have been reported by patients.

Q: What kind of follow-up monitoring is usually needed when starting Metrocor?

Regulatory documents recommend monitoring of total and differential blood counts before and after therapy. Additionally, close monitoring for adverse events is recommended for patients with known severe hepatic (liver) or renal (kidney) impairment.

Q: What is the connection between Metrocor and migraines?

The official safety information lists 'headache' as a commonly reported adverse reaction. Headaches are also a symptom of the disulfiram-like reaction that can occur if the drug is taken with alcohol.

Q: Do younger adults and children use Metrocor?

Official labeling notes that the medication is approved for use in pediatric patients (children) for some indications. Dosing for pediatric use is typically calculated based on body weight, and specific pharmacokinetic differences are noted in infants.

How should Metrocor be stored and disposed of?

How to Store and Dispose of Metrocor: Official Regulatory Information

The storage and disposal instructions for Metrocor are based strictly on regulatory requirements established by government health agencies.

Mandatory Storage Conditions

Metrocor must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture, requiring it to be kept in its original container with the lid tightly closed. It is explicitly required that users Do Not Freeze the product.

Handling and Stability

Observe the expiration date printed on the container. Any preparation or reconstitution, if applicable, must adhere to official label instructions regarding stability and use within a specified time frame. Keep this medicine out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Expired or unused Metrocor must be disposed of properly. The recommended procedure is to use a community drug take-back program. If this option is unavailable, the product should be mixed with an undesirable substance (such as used coffee grounds or dirt) and placed in a sealed container before disposal in the household trash. Medications should generally not be disposed of via flushing or wastewater, unless specifically directed by the authoritative agency.

Metrocor